Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.

ABSTRACT:

Objective

To examine whether the effect of postmenopausal hormone therapy (HT) on brain volumes in women aged 65-79 years differs depending on type 2 diabetes status during postintervention follow-up of a randomized controlled clinical trial.

Methods

The Women's Health Initiative randomized clinical trials assigned women to HT (0.625 mg/day conjugated equine estrogens with or without 2.5 mg/day medroxyprogesterone acetate) or placebo for an average of 5.6 years. A total of 1,402 trial participants underwent brain MRI 2.4 years after the trials; these were repeated in 699 women 4.7 years later. General linear models were used to assess the interaction between diabetes status and HT assignment on brain volumes.

Results

Women with diabetes at baseline or during follow-up

SUBMITTER: Espeland MA 

PROVIDER: S-EPMC4603880 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature